These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 29652301)
1. [The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate]. Khabirov FA; Khaybullin TI; Granatov EV; Shakirzianova SR; Babicheva NN; Kochergina OS; Rakhmatullina EF; Akhmedova GM; Averyanova LA; Yakupov MA; Sabirov ZF Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(3):18-26. PubMed ID: 29652301 [TBL] [Abstract][Full Text] [Related]
3. [Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study]. Korobko DS; Barabanova MA; Bakhtiyarova KZ; Malkova NA; Sivertseva SA; Sokolova AA; Khachanova NV Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):96-103. PubMed ID: 35912564 [TBL] [Abstract][Full Text] [Related]
4. [A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3]. Kotov SV; Kudlay DA; Lizhdvoy VY; Stashuk GA; Magomedova SB Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):107-115. PubMed ID: 31156249 [TBL] [Abstract][Full Text] [Related]
5. [The results of an open prospective study of β-interferon biosimilars (an Yaroslavl' cohort)]. Kasatkin DS; Spirin NN; Boiko AN; Stepanov IO; Spirina NN; Baranova NS Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):68-73. PubMed ID: 27070364 [TBL] [Abstract][Full Text] [Related]
6. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
7. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
8. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
9. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
10. [Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis]. Popova EV; Boyko AN; Bykova OV; Nankina IG; Batysheva TT Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):73-75. PubMed ID: 27456908 [TBL] [Abstract][Full Text] [Related]
11. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region]. Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035 [TBL] [Abstract][Full Text] [Related]
12. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis]. Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis. Velazquez-Villoria D; Macia-Badia C; Segura-García A; Pastor Idoate S; Arcos-Algaba G; Velez-Escola L; García-Arumí J Arch Soc Esp Oftalmol; 2017 Jun; 92(6):273-279. PubMed ID: 28188020 [TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related]
17. [Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)]. Popova EV; Boĭko AN; Vasil'ev AV; Davydovskaia MV; Zavalishin IA; Kotov SV; Krotenkova MV; Khachanova NV; Sharanova SN; Shchur SG; Iakushina TI Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):56-61. PubMed ID: 22951783 [TBL] [Abstract][Full Text] [Related]
18. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530 [TBL] [Abstract][Full Text] [Related]
19. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668 [TBL] [Abstract][Full Text] [Related]